ArticleOncology letters2020
Exosomal miR-34b inhibits proliferation and the epithelial-mesenchymal transition by targeting Notch2 in ovarian cancer.
Article in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- The prognostic value of miR-34 family in ovarian cancer: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- The current trend of exosome in epithelial ovarian cancer studies: A bibliometric review.Frontiers in pharmacology · 2023Pooled it
- Exosomes in Ovarian Cancer: Towards Precision Oncology.Pharmaceuticals (Basel, Switzerland) · 2025Review
- MiR-34b promotes oxidative stress and induces cellular senescence through TWIST1 in human cervical cancer.Translational oncology · 2024Article
- miR‑146a‑5p and miR‑191‑5p as novel diagnostic marker candidates for ovarian clear cell carcinoma.Molecular and clinical oncology · 2024Article
- microRNA-301b-3p from mesenchymal stem cells-derived extracellular vesicles inhibits TXNIP to promote multidrug resistance of gastric cancer cells.Cell biology and toxicology · 2023Article
- Review
- The functions and potential roles of extracellular vesicle noncoding RNAs in gynecological malignancies.Cell death discovery · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exosomal microRNA (miR) can affect signaling pathways in various physiological and pathological conditions, including ovarian cancer (OC). miR-34b, the first microRNA targeted in a human clinical trial for cancer treatment, exhibited decreased expression in several cancer types. However, the biological function of exosomal miR-34b in OC has not been elucidated. In the present study, using reverse transcription-quantitative PCR, it was reported that exosomal miR-34b is downregulated in OC cells. Exosomal miR-34b reduced cell proliferation and epithelial-mesenchymal transition (EMT) in the OC cell line SKOV3. In addition, it was confirmed that Notch2, which is upregulated in SKOV3 cells, is a target of miR-34b. Moreover, exosomal miR-34b and Notch2 levels were found to be negatively correlated. The present data highlights the importance of exosomal miR-34b-mediated inhibition of cell proliferation and EMT, suggesting that exosomal miR-34b has value as a diagnostic biomarker and a potential molecular target for the treatment of OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.